NATIONAL INSTITUTES OF HEALTH
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy
- Conditions
- GliomaHigh Grade GliomaMalignant GliomaGliomasLow Grade Glioma
- Interventions
- Device: 3T MRI scannerDrug: HP 13C Pyruvate
- First Posted Date
- 2019-05-16
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 270
- Registration Number
- NCT03952598
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial
- Conditions
- Multiple Myeloma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirateProcedure: Bone Marrow BiopsyProcedure: Computed TomographyOther: Placebo AdministrationOther: Quality-of-Life AssessmentProcedure: Positron Emission TomographyOther: Questionnaire Administration
- First Posted Date
- 2019-05-08
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1
- Registration Number
- NCT03941860
- Locations
- 🇺🇸
Littleton Adventist Hospital, Littleton, Colorado, United States
🇺🇸Longmont United Hospital, Longmont, Colorado, United States
🇺🇸Rocky Mountain Cancer Centers-Longmont, Longmont, Colorado, United States
Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer
- Conditions
- Metastatic Breast CarcinomaMetastatic HER2-Negative Breast CarcinomaRecurrent Breast CarcinomaAnatomic Stage IV Breast Cancer AJCC v8Metastatic Hormone Receptor-Positive Breast Carcinoma
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionProcedure: Diagnostic ImagingProcedure: EchocardiographyProcedure: Multigated Acquisition Scan
- First Posted Date
- 2019-05-07
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT03939897
- Locations
- 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
🇺🇸Bellevue Hospital Center, New York, New York, United States
🇺🇸UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma
- Conditions
- Metastatic Hepatocellular CarcinomaHepatocellular CancerHepatocellular Carcinoma
- Interventions
- First Posted Date
- 2019-05-06
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 27
- Registration Number
- NCT03937830
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions
- Conditions
- Squamous Lntraepithelial Lesions of VulvaNeoplasms, Squamous CellVulvar HSIL
- Interventions
- Biological: E7 T Cell Receptor (TCR)
- First Posted Date
- 2019-05-06
- Last Posted Date
- 2021-04-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1
- Registration Number
- NCT03937791
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- First Posted Date
- 2019-04-29
- Last Posted Date
- 2025-05-22
- Target Recruit Count
- 74
- Registration Number
- NCT03929601
- Locations
- 🇺🇸
Childrens Hospital of Orange County, Orange, California, United States
🇺🇸Stanford University, Palo Alto, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas
- Conditions
- Advanced LymphomaAnn Arbor Stage III T-Cell Non-Hodgkin LymphomaAnn Arbor Stage IV T-Cell Non-Hodgkin LymphomaRefractory Malignant Solid NeoplasmAnn Arbor Stage III B-Cell Non-Hodgkin LymphomaAnn Arbor Stage IV B-Cell Non-Hodgkin LymphomaRefractory LymphomaRefractory T-Cell Non-Hodgkin LymphomaStage II Pancreatic Cancer AJCC v8Stage IIA Pancreatic Cancer AJCC v8
- Interventions
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2020-09-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT03925428
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
- Conditions
- Peripheral T-cell LymphomasLymphoproliferative DisordersImmune System Diseases
- Interventions
- First Posted Date
- 2019-04-22
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 330
- Registration Number
- NCT03922724
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸National Marrow Donor Program, Minneapolis, Minnesota, United States
Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
- Conditions
- Anaplastic AstrocytomaAnaplastic Astrocytoma, Not Otherwise SpecifiedAnaplastic GangliogliomaAnaplastic Pleomorphic XanthoastrocytomaGlioblastomaMalignant GliomaWHO Grade 3 GliomaWHO Grade 4 Glioma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Lumbar PunctureProcedure: Magnetic Resonance ImagingRadiation: Radiation Therapy
- First Posted Date
- 2019-04-18
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 58
- Registration Number
- NCT03919071
- Locations
- 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Banner Children's at Desert, Mesa, Arizona, United States
🇺🇸Phoenix Childrens Hospital, Phoenix, Arizona, United States
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
- Conditions
- B Acute Lymphoblastic LeukemiaB Lymphoblastic LymphomaDown Syndrome
- Interventions
- Radiation: Radiation Therapy
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 6720
- Registration Number
- NCT03914625
- Locations
- 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸USA Health Strada Patient Care Center, Mobile, Alabama, United States
🇺🇸Providence Alaska Medical Center, Anchorage, Alaska, United States